extract: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
This commit is contained in:
Teleo Agents
parent
024ff0bd29
commit
aa6751e029
4 changed files with 64 additions and 1 deletions
|
|
@ -125,6 +125,12 @@ If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg rega
|
|||
|
||||
Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20*
|
||||
|
||||
India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -49,6 +49,12 @@ The Trump Administration deal establishes a $50/month out-of-pocket maximum for
|
|||
|
||||
Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20*
|
||||
|
||||
OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely when international GLP-1 prices are dropping 50-90% but US prices remain patent-protected at $1,300/month through 2033. This creates structural access failure where coverage loss and price compression move in opposite directions for the population with highest metabolic disease burden.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md:set_created:2026-03-20",
|
||||
"us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md:set_created:2026-03-20"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md:missing_attribution_extractor",
|
||||
"us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-20"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-03-17
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: news analysis
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp1, semaglutide, generics, price-compression, india, patent-expiry, ozempic, wegovy]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-20
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -59,3 +63,18 @@ tags: [glp1, semaglutide, generics, price-compression, india, patent-expiry, oze
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: Direct challenge to existing KB claim — patent expiration is happening NOW (India: March 20, 2026), not in 2030+. The "inflationary through 2035" claim needs geographic scoping at minimum and may be fundamentally wrong at the system level.
|
||||
EXTRACTION HINT: Extractor should propose a scope qualification or replacement for the existing GLP-1 claim, distinguishing US (patent-protected through 2031-2033) from international (price compression beginning 2026) and system-level (inflationary) from risk-bearing payer level (potentially deflationary by 2028-2030).
|
||||
|
||||
|
||||
## Key Facts
|
||||
- India semaglutide patent expired March 20, 2026
|
||||
- 50+ generic brands filed for Indian market launch March 21, 2026
|
||||
- Indian branded semaglutide price: ₹8,000-16,000/month (~$95-190)
|
||||
- Indian generic launch price: ₹3,000-5,000/month (~$36-60), representing 50-60% reduction
|
||||
- Named Indian generic manufacturers: Dr. Reddy's, Cipla, Sun Pharma (Noveltreat, Sematrinity), Zydus (Semaglyn), OneSource Specialty Pharma
|
||||
- Semaglutide patents also expire in 2026: Canada, Brazil, Turkey, China
|
||||
- US semaglutide patents: 2031-2033
|
||||
- University of Liverpool production cost analysis: $3/month ($28-140/year)
|
||||
- Canadian branded Ozempic: ~$400 CAD/month
|
||||
- Canadian projected generic price: $60-100 CAD/month within 12 months
|
||||
- Felix Health (Canada) already forming generic Ozempic waitlist
|
||||
- Oral Wegovy launched January 2026 at $149-299/month vs $1,300+ injectable branded
|
||||
|
|
|
|||
Loading…
Reference in a new issue